跳至主要内容
临床试验/EUCTR2011-004616-36-SK
EUCTR2011-004616-36-SK进行中(未招募)1 期

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD) - EUCLID

AstraZeneca AB0 个研究点目标入组 13,500 人开始时间: 2012年9月19日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
13,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Male and Female patients 50 years old or older
  • 2. Symptomatic peripheral artery disease
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 5400
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 8100

排除标准

  • 1. Patients needing dual anti-platlet drug treatment before start of study
  • 2. Planned revascularisation or amputation
  • 3. Patients with known bleeding disorders
  • 4. Patients with a history of intracranial bleed
  • 5. Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker

研究者

相似试验